July 7, 2015

A while back we were approached by the Leukemia and Lymphoma Society to develop a National Planned Giving Pilot Program to launch in Michigan. We of course accepted the challenge and have been working with the committee to develop the pilot. We have an official November launch and look forward to our upcoming meeting on the 7th with Frank Canning - LLS Senior Director Partnership, Pam Swenk - Executive Director, Illinois, Doug Glazier - Executive Director, Michigan to discuss the additional logistics and planning items for the event!

Truly looking forward to a great meeting with great people!!

Jessica L. Cassidy
Mrs. Michigan International 2015

June 27, 2015

Today was my youngest child's birthday! It amazes me how time has flown and the little tiny peanut she was is no longer. Though I miss my tiny little peanut, it is so exciting to see her grow and learn every day. She is becoming quite the character and is the sweetest cuddle bug I know.

The day of her birthday we were supposed to have a baseball tournament that ended up getting rained out so it was a great opportunity for us to spend the day with her. Even though she was disappointed that she didn't get to hang out with her baseball family we made sure she had a great day which in the end included some of our baseball family.

So proud to have the privilege of being her mother.

Love,
Jessica Cassidy
Mrs. Michigan International 2015

BEAT AML

The Leukemia & Lymphoma Society (LLS) has more good news to share about acute myeloid leukemia (AML)! Celator Pharmaceuticals, an important biotechnology partner in LLS’s Therapy Acceleration Program, released data this week regarding its study of an experimental therapy – a special formulation of two standard chemotherapy drugs to treat elderly patients with high-risk AML. The new therapy performed better than the standard course of treatment currently used. With a patient response rate of more than 47%, this news is very encouraging as it represents a positive advance for patients with few options for effective treatment. We’ve been telling you that AML is an aggressive blood cancer with a survival rate of just more than 25% across all cases and how treatment hasn’t changed for more than 30 years. We believe this is about to change. We set a goal of $300,000 by June 30 to support our Beat AML collaboration with Oregon Health & Science University, and, thanks to supporters like you, we reached it with a few days to spare. But like LLS researchers, we won’t stop there. Please join us in surpassing our goal, because it’s time for a cure. Thank you, Michael C. Copley National Chairman LLS's Beat AML Campaign

If you need help or to learn more about specific blood cancers: www.lls.org/diseaseinformation/ National Office 1311 Mamaroneck Avenue  |  White Plains, NY 10605  |  888.557.7177  |  www.LLS.org © 2015 The Leukemia & Lymphoma Society  |  All Rights Reserved This email was sent to: jcassidy@seniorplanningadvisors.com If you no longer wish to receive these emails, please reply to this message with "Unsubscribe" in the subject line or click on the following link: Unsubscribe To ensure future delivery of emails, please add newsletter@email.lls.org to your safe sender list or address book. About LLS: www.LLS.org | Facebook | Twitter | YouTube | Google+ | Disclaimer | Public Disclosure